What is the appropriate treatment for duodenitis?

Treatment of Duodenitis

For H. pylori-positive duodenitis, treat with high-dose PPI-based triple therapy (PPI twice daily + clarithromycin 500mg + amoxicillin OR metronidazole for 10-14 days) to achieve eradication, which is the only factor that correlates with erosion healing. 1

H. pylori-Associated Duodenitis (Most Common)

Initial Assessment

• Test for H. pylori infection (urea breath test or monoclonal stool antigen test) 2
• All patients with erosive duodenitis in one study were H. pylori-positive, suggesting this is the primary etiology 1

First-Line Treatment Regimen

Use high-dose PPI twice daily - this increases eradication rates by 6-10% compared to standard dosing 2. The maximal benefit comes from using 40mg esomeprazole or rabeprazole twice daily rather than first-generation PPIs 2.

Triple therapy options (both equivalent): 2

• PPI + clarithromycin 500mg + amoxicillin (PCA regimen)
• PPI + clarithromycin 500mg + metronidazole (PCM regimen)

Duration: 10-14 days rather than 7 days improves eradication success by approximately 5% 2

Treatment Outcomes

When H. pylori eradication is successful:

• 86% achieve duodenal erosion healing 1
• Only 37% heal if eradication fails 1
• H. pylori eradication is the only variable that correlates with erosion healing (odds ratio 10) 1

Confirm Eradication

• Test at least 4 weeks after completing treatment 2
• Use urea breath test or validated monoclonal stool test - never serology 2
• For persistent erosions at 1 month, retest at 6 months as delayed healing can occur 1

Second-Line Treatment (After First-Line Failure)

Use either: 2

• Bismuth-containing quadruple therapy, OR
• Levofloxacin-containing triple therapy

Important caveat: Rising levofloxacin resistance rates should be considered 2

NSAID-Associated Duodenitis

Risk Reduction Strategy

• Use lowest effective NSAID dose for shortest duration 3
• Consider H. pylori eradication - it decreases peptic ulcers in NSAID-naive patients starting therapy 3
• Note: H. pylori eradication does NOT protect patients with previous ulcer history on NSAIDs 3

Gastroprotection

PPI cotherapy is the most practical option despite lack of large outcome trials 3:

• Reduces endoscopic NSAID-related ulcers by approximately 90% 3
• In one study, omeprazole reduced recurrent bleeding from 18.8% to 4.4% compared to H. pylori eradication alone 3

Alternative: Misoprostol (only agent with large outcome trial data):

• Reduces GI complications by 40% 3
• Decreases gastric ulcers by 74% and duodenal ulcers by 53% 3
• Requires ≥600mg/day but causes diarrhea, abdominal pain, nausea in ~20% of patients 3

H2-receptor antagonists: Decrease duodenal ulcers but NOT gastric ulcers - less preferred 3

Non-H. pylori, Non-NSAID Duodenitis

Eosinophilic Duodenitis

• Consider elimination diet approaches 4
• For refractory cases: JAK inhibitors (upadacitinib) show emerging efficacy 5, 6

Non-erosive Duodenitis

• H2-receptor antagonists can relieve symptoms and promote healing 7
• Nizatidine 150mg twice daily shows particular promise for continuous acid suppression 7

Common Pitfalls

1. Don't assume all duodenitis is H. pylori-related - consider celiac disease, eosinophilic disorders, Crohn's disease, and medication effects 8

2. Don't use serology to confirm eradication - it remains positive long after successful treatment 2

3. Don't test too early - wait at least 4 weeks post-treatment to avoid false-positive results 2

4. Don't use standard-dose PPIs - high-dose twice-daily regimens significantly improve outcomes 2

5. Account for patient factors affecting treatment success: smoking (doubles failure risk), high BMI, and functional dyspepsia all reduce eradication rates 2